Insider · CIK 0001472322
Nantahala Capital Management, LLC
Files at AYTU (AYTU BIOPHARMA, INC), EVOK (Evoke Pharma Inc), TLPH (TALPHERA, INC.). First filing Jan 30, 2025, latest Jan 30, 2025.
In brief
Nantahala Capital Management, LLC files SEC Form 4 as 10% owner at EVOK (Evoke Pharma Inc), and also at AYTU (AYTU BIOPHARMA, INC), TLPH (TALPHERA, INC.). Since Jan 30, 2025, Nantahala Capital Management, LLC has reported 0 open-market buys worth $0 and 1 open-market sell worth $180, the latest filed on Jan 30, 2025.
A track record needs three past buys with six months of prices behind them; Nantahala Capital Management, LLC has 0, so none is measured yet.
The newest scored trade: sold $180 of EVOK on Jan 28, 2025, filed Jan 30, 2025, scored 12 (weak).
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | TLPH TALPHERA, INC. | AGrant or award Pre-Funded Warrantsderivativeindirect: See Footnote | +4,266,211 | $0.59 | $2.5M | 18,822,267 | Mar 17, 2026 |
| Dec 17, 2025 | EVOK Evoke Pharma Inc | JOther Common Stockindirect: See Footnote | -148,153 | $11.00 | $1.6M | 0 | Dec 19, 2025 |
| Dec 17, 2025 | EVOK Evoke Pharma Inc | JOther Prefunded Warrantsderivativeindirect: See Footnote | -433,962 | $11.00 | $4.8M | 0 | Dec 19, 2025 |
| Dec 17, 2025 | EVOK Evoke Pharma Inc | JOther Series A Common Stock Purchase Warrantsderivativeindirect: See Footnote | -117,019 | $4.71 | $551k | 0 | Dec 19, 2025 |
| Dec 17, 2025 | EVOK Evoke Pharma Inc | JOther Series C Common Stock Purchase Warrantsderivativeindirect: See Footnote | -117,019 | $4.71 | $551k | 0 | Dec 19, 2025 |
| Dec 17, 2025 | EVOK Evoke Pharma Inc | JOther Amended Series A Common Stock Purchase Warrantsderivativeindirect: See Footnote | -158,531 | $10.99 | $1.7M | 0 | Dec 19, 2025 |
| Dec 17, 2025 | EVOK Evoke Pharma Inc | JOther Amended Series C Common Stock Purchase Warrantsderivativeindirect: See Footnote | -250,627 | $10.99 | $2.8M | 0 | Dec 19, 2025 |
| Jun 6, 2025 | AYTU AYTU BIOPHARMA, INC | POpen-market purchase Prefunded Warrantsderivativeindirect: See footnote | +4,000,000 | $1.50 | $6.0M | 4,815,217 | Jun 9, 2025 |
| Mar 31, 2025 | TLPH TALPHERA, INC. | AGrant or award Pre-Funded Warrantsderivativeindirect: See footnote | +4,266,211 | $0.59 | $2.5M | 11,510,601 | Apr 2, 2025 |
| Jan 28, 2025 | EVOK Evoke Pharma Inc | SOpen-market sale Common Stockindirect: See footnote | -41 | $4.39 | $180 | 148,153 | Jan 30, 2025 |
Questions about Nantahala Capital Management, LLC
Answered from the filings on this page, as of the latest one.
Is Nantahala Capital Management, LLC buying or selling?
Not in the last 12 months. Nantahala Capital Management, LLC's latest open-market trade on SEC Form 4 was sold $180 of EVOK on Jan 28, 2025.
How did Nantahala Capital Management, LLC's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Nantahala Capital Management, LLC has 0.
Where does Nantahala Capital Management, LLC file Form 4?
Nantahala Capital Management, LLC has filed Form 4 at EVOK (Evoke Pharma Inc); AYTU (AYTU BIOPHARMA, INC); TLPH (TALPHERA, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.